Purpose: Cefazolin/tobramycin, cefuroxime/gentamicin, and moxifloxacin were compared using bacterial keratitis isolates to determine whether empiric therapy constituted optimal antibacterial treatment.
B acterial keratitis is generally treated empirically without or with the subsequent knowledge of laboratory identification and antibiotic susceptibility studies. Figure 1 provides a distribution of Gram-positive and Gram-negative bacteria that were isolated from the corneas of patients with bacterial keratitis at The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA. This distribution of bacterial pathogens supports the use of "broad-spectrum" antibacterial drugs to empirically treat suspected bacterial keratitis in a timely manner. Antibiotics for the coverage of Gram-positive and Gram-negative negative are formulated at high concentration to provide broad-spectrum therapy. In the United Kingdom (Dua H, Bacterial Infections, EVER 2010, October 6, Supplement pg 21), cefuroxime, a second-generation cephalosporin, and gentamicin, an aminoglycoside, is the favored combination for empiric therapy, whereas cefazolin, a firstgeneration cephalosporin, along with tobramycin, another aminoglycoside, are commonly used in the United States. 1 The first-generation cephalosporins are considered to be more efficacious than the second-generation cephalosporins for Gram-positive bacterium, 2 and tobramycin was an improvement over gentamicin for the coverage of Pseudomonas aeruginosa, 3 a Gram-negative bacteria. Neither of these combinations is commercially packaged for keratitis care.
A commercially formulated broad-spectrum antibiotic to act as monotherapy for empiric bacterial keratitis treatment seems to be advantageous for wide availability and simplified use. Monotherapy with a fluoroquinolone has been practiced for empiric therapy since the inception of the secondgeneration and third-generation fluoroquinolones (ciprofloxacin, 1 ofloxacin, 4 and levofloxacin 5 ) and the fourth-generation fluoroquinolones (moxifloxacin 6 and gatifloxacin 7 ). Another fourth-generation fluoroquinolone, besifloxacin (Besivance; Bausch and Lomb, Rochester, NY), also has potential for topical keratitis treatment. The fourth-generation fluoroquinolones have been reported to be more potent and less likely to promote resistance than the second-generation fluoroquinolones. 8 We hypothesized that the cefazolin/tobramycin combination would provide broader empiric bacterial keratitis coverage than the cefuroxime/gentamicin combination and monotherapy with a fourth-generation fluoroquinolone. The hypothesis was tested by determining the in vitro susceptibilities of the regimens against a panel of bacterial keratitis pathogens that were chosen on the basis of incidence and chronologic order to represent the correct incidence of infection. We determined whether empiric antiinfective coverage was optimal with potency comparisons within the cephalosporin and aminoglycoside groups.
MATERIALS AND METHODS
The incidence of bacterial keratitis was determined from 1993 to 2010 at The Charles T. Campbell Ophthalmic Microbiology Laboratory at The University of Pittsburgh Medical Center, Pittsburgh, PA ( Fig. 1 ). Based on percent incidence of infection, 27 Staphylococcus aureus, 16 P. aeruginosa, 10 Serratia marcescens, 4 Moraxella lacunata, 3 Haemophilus influenzae, 9 coagulase-negative staphylococci, 7 Streptococcus viridans, 6 Streptococcus pneumoniae, 7 assorted Gram-positive isolates, and 11 assorted Gram-negative isolates were tested for minimum inhibitory concentration (MICs) using E-tests (AB BioDisk, Dalvagen, Sweden) with National Committee for Clinical Laboratory Standards guidance. [8] [9] [10] The antiinfectives tested were cefazolin, cefuroxime, tobramycin, gentamicin, and moxifloxacin. The 100 isolates were consecutively retrieved, without patient identification markers, in reverse chronologic order from March 4, 2011. All isolates were collected from the corneas of patients with the clinical presentation of bacterial keratitis. These isolates are part of the clinical bank collection used to validate new antibiotics and diagnostic testing and monitoring of antibiotic resistance that is necessary for clinical laboratory certification.
Previous 2000 National Committee for Clinical Laboratory Standards (now CLSI, Clinical and Laboratory Standards Institute, Wayne, PA) were used to interpret susceptibility using guidelines based on serum concentrations. 9 There are no standards for interpreting topical ocular treatment, but the serum standards can be used if it is assumed that the antibiotic concentrations in the ocular tissue are equal or greater than the antibiotic concentrations that can be attained in the serum. [8] [9] [10] This assumption is based on the high concentration of topical antibiotic that crosses the corneal epithelium to reach higher concentration in the ocular tissue than would systemic therapy. These elevated concentrations are in excess of the required MICs to denote susceptibility in the blood serum. The newer 2009 Clinical and Laboratory Standards Institute standards have changed to accommodate the refinement of serum level susceptibility, but these do not reflect any change for topical therapy and have no bearing on the ophthalmic interpretation. 11 Experience (The first author has 35 years in susceptibility testing as an ophthalmic microbiologist.) and the lack of supportive data for intermediate susceptibility have dictated that intermediate susceptibility has no meaning for ocular isolates, and high antibiotic concentrations in the ocular tissue should allow for intermediate values to be interpreted as susceptible. It is important to interpret susceptibility with the same standards between periods (2000 vs. 2009) for nonbiased comparisons.
The in vitro coverage (susceptible to at least 1 antibiotic susceptible to both antibiotics) was determined for the cefuroxime/gentamicin and cefazolin/tobramycin combinations, and these were further compared with moxifloxacin monotherapy. The susceptibilities of individual coverage for moxifloxacin, gentamicin, tobramycin, cefazolin, and cefuroxime were also determined.
In addition, the MICs were used to compare the potencies within the aminoglycoside and cephalosporin drug classes. The antiinfective in a drug class with the lower MICs is deemed the more potent antiinfective. Potency cannot be compared between classes (ie, tobramycin vs. cefazolin) of antiinfectives using MIC data. 12 
Statistical Analysis
All in vitro susceptibilities for the combinations and individual antiinfectives were tested for differences using x 2 analysis (MiniTab, State College, PA). The Mann-Whitney test (MiniTab) for nonparametric comparisons was used to determine any MIC differences for gentamicin and tobramycin against Gram-negative bacteria and cefazolin and cefuroxime against Gram-positive bacteria. A P value of 0.05 or less was used to define a significant difference.
RESULTS
The bacterial corneal isolates were retrieved during the following periods: S. aureus (November 28, 2009 to Figure 2 depicts the percentage of bacterial keratitis isolates covered by at least 1 antibiotic. Cefuroxime/gentamicin (97%, 97 of 100) was statistically equal to cefazolin/tobramycin (93%, 93 of 100) and moxifloxacin (92%, 92 of 100) (P = 0.29, x 2 ). Cefuroxime/gentamicin did not cover one isolate each of H. influenzae, P. aeruginosa, and Stenotrophomonas maltophilia. Cefazolin/tobramycin did not cover 2 isolates of S. aureus and 1 isolate each of H. influenzae, S. maltophilia, S. marcescens, S. viridans, and Chryseobacterium indologenes.
Moxifloxacin did not cover 3 isolates of coagulasenegative Staphylococcus and 1 isolate each of S. aureus, H. influenzae, S. viridans, Morganella morganii, and Enterococcus species. Figure 2 depicts the percentage of bacterial keratitis isolates covered by both antibiotics for each regimen. Double coverage was equivalent (P = 0.77, x 2 ) for cefuroxime/gentamicin (42%, 42 of 100) and cefazolin/tobramycin (40%, 40 of 100). Figure 3 depicts the individual coverage for all 5 antiinfectives. Individual coverage determined that moxifloxacin (92%) was equal to gentamicin (89%) (P = 0.47, x 2 ), although both covered more than tobramycin (74%) (P = 0.001, x 2 ). Tobramycin (74%) covered more (P = 0.035, x 2 ) than cefazolin (58%) and cefuroxime (52%), which were statistically equal (P = 0.494, x 2 ). Figure 4 depicts the distribution of methicillin-resistant Staphylococcus aureus (MRSA) antibiotic susceptibility among 9 isolates. All 9 MRSA isolates were susceptible to gentamicin, whereas only 5 were susceptible to tobramycin. Only 2 MRSA isolates were susceptible to both cefazolin and cefuroxime. Five MRSA isolates were susceptible to moxifloxacin.
Potency analysis for Gram-negative bacteria determined that P. aeruginosa MICs (n = 16) for tobramycin (median = 1.0 mg/mL) were significantly lower (more potent) than gentamicin (median = 3.0 mg/mL) (P = 0.00001, Mann-Whitney). The S. marcescens MICs (n = 10) for gentamicin (median = 1.75 mg/mL) were significantly lower (more potent) than tobramycin (median = 3.0 mg/mL) (P = 0.0065, Mann-Whitney). For other Gram-negative bacteria (n = 11), the MICs were equivalent (equally potent) to gentamicin (median = 1.5 mg/mL) and tobramycin (median = 1.5 mg/mL) (P = 0.79, Mann-Whitney).
Potency analysis for Gram-positive bacteria determined that S. aureus MICs (n = 27) for cefazolin (median = 1.0 mg/mL) were significantly lower (more potent) than cefuroxime (median = 2.0 mg/mL) (P = 0.0004, Mann-Whitney). The S. pneumoniae MICs (n = 6) for cefuroxime (median = 0.0195 mg/mL) were significantly lower (more potent) than cefazolin (median = 0.094 mg/mL) (P = 0.005, Mann-Whitney). The MICs for coagulase-negative Staphylococcus (n = 9) to cefazolin (median = 0.75 mg/mL) and cefuroxime (median = 1.5 mg/mL) were equivalent (equally potent) (P = 0.21, Mann-Whitney). The MICs for S. viridans (n = 7) to cefazolin (median = 0.38 mg/mL) and cefuroxime (median = 0.19 mg/mL) were equivalent (equally potent) (P = 0.12, Mann-Whitney). The MICs for other Gram-positive bacteria (n = 7) to cefazolin (median = 0.8 mg/mL) and cefuroxime (median = 1.5 mg/mL) were equivalent (equally potent) (P = 0.52, Mann-Whitney).
DISCUSSION
The empiric treatment of bacterial keratitis is an important issue especially with the lack of laboratory support for confirming adequate coverage. In general, small corneal defects with infiltrates less than 2 mm precipitated by contact lens use may not be candidates for laboratory studies because most are either sterile or respond nicely to empiric therapy. Smaller defects can become larger defects, and if these are not adequately covered by empiric therapy, then these defects could result in corneal ulceration and extended therapy.
The strength of our study is that the corneal isolates were selected consecutively on the basis of a weighted incidence of infection and not on a bias of select antibiotic susceptibility. The ideal study would be a controlled clinical trial, but no trial could compare multiple antibacterial regimens on single patients. It is highly unlikely that a clinical trial for comparing bacterial keratitis treatment regimens would be funded through governmental sources or by industry. A reasonable position by the government is that the industry should provide evidence of the efficacy of antibacterial drugs and a pharmaceutical company would prefer a guaranteed favorable demonstration of its drug product.
In vitro studies have been used successfully to guide in vivo therapy. Although we do not have clinical data for the in vivo efficacy of the regimens used to treat the bacterial infections in the present study, we assume that all the patients resolved their bacterial keratitis with empiric and subsequent directed therapy. As an in vitro study, other factors such as drug penetration, dosing schedule, innate immunity, virulence factors, adjunctive measures, and patient compliance were not accounted in the critical management of acute bacterial keratitis.
In the present in vitro study, we rejected the hypothesis that empiric therapy of bacterial keratitis would be best covered with cefazolin and tobramycin rather than cefuroxime and gentamicin. In addition, neither combination provided wider coverage than moxifloxacin monotherapy. It seemed that topical empiric therapy with either combination or moxifloxacin monotherapy was equivalent. The next question would be whether empiric therapy is an optimal therapy based on laboratory testing.
Potency studies indicate that the empiric combination of cefazolin and tobramycin would be best for covering S. aureus and P. aeruginosa keratitis. Gentamicin may provide an advantage over tobramycin for treating S. marcescens, and cefuroxime may provide an advantage over cefazolin for treating S. pneumoniae. As always, changes in therapy after empiric treatment should be considered based on the ophthalmologist's clinical impression and experience.
We did not include vancomycin and ciprofloxacin as candidates for empiric therapy. Vancomycin is an excellent Gram-positive antibiotic and is the agent of choice in the treatment of MRSA. Vancomycin-resistant S. aureus and vancomycin-resistant Enterococcus have not been yet a problem in the treatment of ocular infections. Some reserve vancomycin for selected ocular infections to avoid possible acquired resistance. Vancomycin should be considered as an empiric therapy in bacterial keratitis cases where MRSA is a possibility or highly suspected (ie, patient exposure, health care worker).
Ciprofloxacin is a second-generation fluoroquinolone that could be used for the treatment of P. aeruginosa keratitis when topical therapy using tobramycin or moxifloxacin is not providing satisfactory results. Ciprofloxacin has been reported to be the most potent fluoroquinolone for covering P. aeruginosa; however, it is less potent and therefore more at risk for the selection of resistance with S. aureus. 8, 10 Although vancomycin is the first-line antibiotic to treat MRSA keratitis, gentamicin seemed to be an alternative therapy in the present study. Although gentamicin tested to provide 100% coverage for MRSA keratitis infection, we highly advocate that laboratory susceptibility testing supports this coverage for each keratitis case. It must also be noted that our present in vitro study does not support the use of topical cefazolin for the treatment of MRSA, but prior data from our laboratory, 13 reports by others, [14] [15] [16] and success in our animal model 17 indicate that coverage is possible. Cefazolin can bind to the penicillin-binding protein 2a prime, which is coded by the mecA gene and thereby prevents cell wall formation.
In the present study, moxifloxacin demonstrated to be an adequate choice for empiric therapy but laboratory confirmation should support treatment because of reports of fluoroquinolone resistance among P. aeruginosa and S. aureus isolates. [18] [19] [20] [21] [22] All fluoroquinolones are not the same, and one should not assume that there is equal coverage with the second-and fourth-generation fluoroquinolones. Bacterial resistance is more likely to occur with the second-generation fluoroquinolones because a single mutation (DNA gyrase or topoisomerase IV) is sufficient to confer resistance, whereas 2 mutations (DNA gyrase and topoisomerase IV) are necessary to confer resistance to the fourth-generation fluoroquinolone antiinfectives such as moxifloxacin. 18 It can be reasoned that increased resistance to the fluoroquinolones can be compounded with widespread surgical prophylaxis, improper dosing with a concentration-dependent antiinfective, mixing the usage of second-and fourth-generation fluoroquinolones to create step mutations, and chronic dosing.
In summary, cefazolin/tobramycin, cefuroxime/gentamicin, and moxifloxacin monotherapy seemed to be equivalent for the empiric topical treatment of bacterial keratitis. Although, in general, broad-spectrum empiric therapy may not represent optimal management, laboratory studies should guide best possible therapy.
